- Gujarat Themis Biosyn is one of the few companies in India that can make medicines using fermentation - the same process behind beer and bread, but tuned to grow high-value antibiotic compounds instead. It started in 1981 as a joint venture between the Government of Gujarat and Chemosyn (P) Ltd., spent decades as a contract manufacturer, and then in 2020 tore up that model to sell directly to the market under its own name. Everything the company does flows from a single idea: own the rare fermentation know-how, then climb the value chain - from raw intermediates to finished drugs to a global branded portfolio - using the cash and credibility of each step to fund the next.
Business segments
A single fermentation engine that has evolved into three stages of vertical integration - intermediates today, APIs tomorrow, and a global branded portfolio the day after - with a Japanese biotech acquisition adding an entirely new CDMO dimension.
1. Fermentation-based intermediates: the scarce core that everything else is built on
GTBL makes Rifamycin S and Rifamycin O through fermentation - a capability so rare in India that only a handful of companies remain, while most of the country’s needs are met by imports.
- One of the last ones standing - from a pharmaceutical fermentation perspective, about a dozen or more Indian companies could not survive pricing competition from China; today probably only a handful remain, with GTBL among them. Many fermentation-made products are simply not manufactured in India, so the country relies heavily on imports.
- The molecules are old but irreplaceable - Rifamycin S goes into Rifampicin, the frontline TB drug, while Rifamycin O goes into Rifaximin, used for traveller’s diarrhoea and irritable bowel syndrome. These products are more than a decade old with no replacement, and demand continues to grow.
- Sold to Indian formulation makers, not to patients - the business is B2B: GTBL sells intermediates to domestic pharma companies like Lupin, who turn them into finished tablets and sell the API into global markets. Relationships are long-standing and described by management as “win-win”.
- From cost-plus captive to market-price independence - until FY20, GTBL operated under a contract manufacturing model where a single customer supplied raw materials and GTBL earned a fixed margin per kilo with zero cost risk. The shift to direct procurement and market-based pricing increased risk but also improved realisations and opened up market access.
- 990 KL of fermentation capacity at a single Vapi site - the plant, which employs roughly 200 people, recently completed an expansion from 450 KL to 990 KL of fermentation capacity, with fungible production capability of up to 16,000 kg per month across its current products.
2. API forward integration: moving one step closer to the finished pill
A new multi-purpose API plant at the same Vapi site began commercial production in May 2025, designed to convert GTBL’s own intermediates into active pharmaceutical ingredients for both domestic and export markets.
- Three products at once under one roof - the API facility has three distinct production streams within a single plant, allowing simultaneous manufacturing of three different molecules. It is built to be compliant with global regulatory norms, specifically targeting the US and Europe.
- Rifapentine is the lead target - the company believes the WHO is likely to recommend Rifapentine as the preferred TB treatment over Rifampicin, and the drug also has potential for treating latent tuberculosis. GTBL is developing additional APIs to add to this forward-integrated portfolio.
- Zero Liquid Discharge built in - a ZLD plant at the Vapi site was in the final stages of commissioning, designed to treat industrial effluent and recycle treated water, with the necessary environmental clearance already obtained for the capacity expansion.
3. Sanofi brand portfolio: a ready-made global front end
In April 2026, GTBL agreed to buy 13 established branded generic anti-TB and anti-infective products from Sanofi for EUR 158 million - giving it instant access to pharmacy shelves across more than 55 countries without buying a single factory.
- Brands, not bricks - the acquisition includes marketing authorizations, brands, regulatory dossiers, and inventory, but no legal entity, manufacturing facilities, or employees. That means GTBL gets the commercial engine without taking on manufacturing overhead.
- EUR 62 million in sales already on the books - the portfolio generated approximately EUR 62 million in net sales for the year ended 2025, with roughly 70% of revenue coming through the retail channel. Key molecules include Levofloxacin, Rifampicin, and Rifapentine - all classified as WHO Essential Medicines and EU Critical Drugs.
- Vertical integration in one deal - the acquisition completes the intermediates-to-API-to-finished-dosage chain, with additional upside from API integration, cost optimisation, and the reactivation of dormant marketing authorizations across the 55-plus-country footprint. The transaction is expected to close by end-December 2026, subject to antitrust and foreign investment approvals.
4. MicroBiopharm Japan: a fermentation CDMO platform with biotech depth
In May 2026, GTBL agreed to acquire 100% of MicroBiopharm Japan - a company that has been serving the world’s top six pharma companies for over 20 years - adding oncology APIs, plasmid DNA, and enzyme-based manufacturing to its toolkit.
- A JPY 21.5 billion entry into Japan’s biotech CDMO space - the acquisition, to be funded through a mix of debt and equity, brings estimated revenue of approximately JPY 9.5 billion (roughly INR 570 crores) for FY26, with 40% of revenues coming from outside Japan across Asia, Europe, and North America.
- Proprietary platforms, not just capacity - MBJ’s technology portfolio includes a P450 enzyme library, plasmid DNA manufacturing, ADC (antibody-drug conjugate) conjugation, and strain and process optimisation platforms. The deal is intended to build a next-generation, discovery-led CDMO platform that spans APIs, biologics, and precision fermentation.
- Acquired through a newly created Japanese subsidiary - GTBL incorporated Themis Biosyn Japan Limited on 19 May 2026 specifically to execute this transaction, which is subject to Japan’s Foreign Exchange and Foreign Trade Act approval and expected to close in Q2 FY2027.
Hybrid renewable power
An 18 MW captive wind-solar hybrid plant in Gujarat is being built to lower power costs and reduce dependence on the grid - a cost-saving infrastructure play, not a standalone business.
- Wind plus solar for round-the-year consistency - the hybrid configuration is designed to deliver more reliable green power across seasons than either technology alone could provide.
- Captive consumption only - the project is designed to reduce power costs, lower the company’s carbon footprint, and support environmental sustainability at its manufacturing site, with no indication of third-party power sales.
Group structure and partners
GTBL was born as a government joint venture with South Korean technology, but a series of structural moves - the exit of its Korean partner, an aborted merger with its sister company, and two transformative 2026 acquisitions - have reshaped it into an independent, globally ambitious fermentation platform.
- The Korean chapter is closed - Yuhan Corporation of South Korea, GTBL’s oldest technology partner, held a 26.50% stake until September 2021, when promoter Pharmaceutical Business Group (India) Limited bought it out entirely for INR 57.75 crores, giving the promoter group consolidated control at 74.99%. The decoupling was explicitly intended to free GTBL to formulate and execute its own growth strategies.
- A merger was proposed, then withdrawn - in November 2024, the boards of GTBL and Themis Medicare Limited (TML) - a related party that makes finished formulations and shares analytical services and infrastructure with GTBL - approved a scheme to amalgamate the two companies. By June 2025, the board withdrew the scheme, deciding that GTBL could deliver better value by focusing independently on its core fermentation business and pursuing both organic and inorganic opportunities.
- The 2026 acquisitions create a multi-entity group - the Sanofi deal is an asset purchase (brands, dossiers, inventory - no legal entity), while the MicroBiopharm Japan deal is a 100% share purchase through a newly created Japanese subsidiary, Themis Biosyn Japan Limited. GTBL also incorporated subsidiaries in Ireland - Themis Biosyn Ireland Private Limited and its wholly owned step-down, Themis Biosyn Private Limited - in May and June 2026. As of FY25, GTBL had no subsidiaries at all; the structure has transformed within a single fiscal year.